Management and prognosis of acute extracranial internal carotid artery occlusion.

Acute occlusion of the internal carotid artery is the underlying etiology in 4 to 15% of all ischemic strokes. The clinical presentation varies considerably ranging from asymptomatic occlusion to severe ischemic strokes. Substantial differences in the acute management of acute symptomatic internal carotid artery occlusions (ICAO) exists between centers. Thusly, we comprised a narrative review of the natural course of acute ICAO and of available treatment options [i.v. thrombolysis, endovascular thrombectomy and stenting, bypass between the superficial temporal and the middle cerebral arteries (MCA) and carotid endarterectomy (CEA)]. We found that very few randomized treatment trials have been performed in patients acute symptomatic ICAO. Most evidence stems from case series and observational studies. Especially in older studies the intracranial vessel status has rarely been considered. After revision of these studies we concluded that the mainstay of the acute management of acute symptomatic ICAO is i.v. thrombolysis when applied within the label and in combination with mechanical thrombectomy in case of intracranial large vessel occlusion. In cases without intracranial large vessel occlusion mechanical thrombectomy of acute ICAO is associated with a risk of distal embolization. More research on prognostic parameters is needed to better characterize the risk of decompensation of collateral flow and to better define the time-window of intervention. When mechanical thrombectomy fails or is not available, surgical approaches are an alternative in selected patients. 2020 Annals of Translational Medicine. All rights reserved.

Introduction

Acute occlusion of the internal carotid artery occlusion (ICAO) is the underlying etiology for 4–15% of all ischemic strokes (1,2) and mainly based on pre-existing atherosclerotic lesions evident in 53–55% of cases (3). Stenosis progression or plaque rupture with secondary thrombosis are believed to be the most common causes of acute ICAO (3,4). Other etiologies like atrial fibrillation or arterial dissection have a considerably lower prevalence in these patients (5,6). Clinically, acute ICAO can cause a variety of symptoms ranging from asymptomatic courses to transient ischemic symptoms or severe ischemic strokes (7). Lesion pattern, clinical presentation and risk of recurrent ischemic events are heavily dependent on occlusion sites. Factors like tandem occlusion of the ICA together with the middle cerebral (MCA) or anterior cerebral artery (ACA), insufficient collateral reserve for the occluded artery and systemic hemodynamic compromise, such as pre-existing cardiomyopathy and low blood pressure are associated with likelihood of ischemic stroke and worse outcomes (8-10). Annual recurrence rates of ischemic events in symptomatic acute ICAO reportedly lie between 10% and 18%, with stump embolisms into downstream circulation being the most common cause (4). Additionally, in chronically occluded internal carotid arteries (i.e., without initial ischemic symptoms) the risk for ipsilateral TIA/stroke is 5–7% per annum even under sufficient secondary prevention strategies (9,11-13). Neurologically, patients with acute ICAO most frequently present with contralateral hemiparesis (4) while transient ischemic attacks (TIA) in the territory of the anterior circulation or retinal ischemia represent the most common ischemic symptoms in recurrence (14).

Acute ICAO frequently leads to severe ischemic strokes with an adverse functional outcome with 40–69% of patients showing residual severe neurological deficits and only 8–20.6% having a modified Rankin Scale (mRS) score ≤2 (15-17) in follow-up as well as a high mortality of 16–55% (8). In cases of tandem MCA or ACA occlusion in addition to ICAO, outcomes are considered even more severe than in extra-cranial ICAO only (18). But as studies showed, fast recanalization of occluded arteries greatly improved clinical and functional outcome, which highlights the need for safe and effective treatment strategies in this subgroup of ischemic stroke patients (6,19). This literature review focuses on current evidence concerning up to date acute treatment options in ischemic stroke patients with symptomatic acute ICAO.

Approach: best medical—i.v. thrombolysis

I.v. thrombolysis is known to be an effective treatment option for all acute ischemic stroke patients for two decades now, with an estimated risk of symptomatic thrombolysis-associated intracranial hemorrhage of about 5% when administered within the label (20-24). Yet, it is still unclear if the subgroup of patients with acute ICAO and ischemic stroke also benefit from this treatment. Clinical studies are scarce and to date only one randomized controlled trial compared i.v. thrombolysis against the natural course of acute ICAO patients. This trial [Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET)] even suggested that subjects receiving recombinant tissue plasminogen activator (rtPA) had worse functional outcomes than untreated patients (i.v. rtPA vs. natural course: mRS ≤20% vs. 23.3%; P=0.257) (25). This finding was supported by further case control series (i.e., ICARO studies) not showing a significant treatment effect on 3-month outcome (1,6,26-28). One major limitation of these early pre-thrombectomy trials, especially EPITHET, that i.v. rtPA was administered up to six hours after symptom onset (25). Even though most studies reported low recanalization rates (4.4–12.5%) in general (1,6,27,28), the probability was higher (10% to 30%) if treatment was initiated within three hours of symptom onset (26), and considerably higher than in the natural course (8.6%) (29). The fairly low recanalization rates can be explained by the fact that thrombolytic drugs are reliant on their delivery to and distribution within the blood clot in addition to the local pressure gradient adjacent to the clot (16) and the thrombus size (27).

The conclusions for clinical practice that can be drawn from all these studies is limited. In the few evaluations with information on the intracranial vessel status higher mortality rates and worse treatment effect of i.v. thrombolysis in patients having tandem occlusions compared to those with extra-cranial carotid artery occlusion only has been reported (30-32).

In summary, systemic i.v. thrombolysis seems to be a plausible but not highly effective treatment option in acute ICAO patients, which should not be withheld when used within the label.

Approach: endovascular—thrombectomy and stenting

Since the multiple positive randomized controlled trials of acute thrombectomy in patients with ischemic stroke due to large intracranial vessel occlusion of 2015, intra-arterial revascularization gained more and more momentum revealing indications and expanding time-to-treatment-windows previously uncharted by medical treatment alone (33-37).

In the setting of ICAO in combination with intracranial large vessel occlusion (tandem occlusion), endovascular techniques are intriguing, and widely applied in clinical practice in those centers that have sufficient expertise and equipment to be readily available 24/7 (38). Studies, with rather small sample sizes (50–100 subjects), concluded that clinical outcomes in endovascular treatment of tandem pathologies are similar to those with endovascular therapy due to intracranial occlusion only (39-41).

Large uncertainties exist whether ICAO should be treated by aspiration and balloon angioplasty alone or in combination with acute stenting, and heterogeneity of approaches have been documented (38,41). Arguments against acute ICA stenting are the (perceived) need for dual antiplatelet therapy that (probably) increases risk of intracerebral hemorrhage, especially in subjects with large infarct volume. Recent retrospective evaluations of the TITAN registry (thrombectomy in Tandem lesions) though hint that the use of antiplatelet therapy in this setting is save (42).

Two recent meta-analyses, including over 25 studies and more than 1,500 patients in total, revealed that time-to-recanalization was significantly longer in subjects receiving stenting prior to thrombectomy compared to those with thrombectomy only, but clinical outcome characteristics such as favorable outcome (50% vs. 53%), intracranial hemorrhage (8% vs. 7%) mortality (16% vs. 14%) and recanalization rates (80% vs. 75%) did not differ (43,44). Consequently if available, stenting of upstream ICAO in tandem vessel occlusion seems to be a feasible option, but methodology differed in clinical application even on this level. A multi-center study of 165 patients compared an antegrade strategy (stenting prior to thrombectomy) to a retrograde strategy (thrombectomy prior to stenting). In this study, the retrograde method performed well with significantly higher rates of vessel reperfusion (92% vs. 56%) and favorable outcomes (44% vs. 30%) compared to those receiving stenting prior to thrombectomy (45). These results were replicated by smaller studies favoring the retrograde methodology (46,47).

Only few studies focused on endovascular treatment in the setting of symptomatic isolated acute cervical ICAO (non-tandem pathology). One study of 22 patients found that recanalization could be achieved in 77% with following clinical improvement occurring in 46% of subjects and 50% having favorable clinical outcome 3 months after treatment (48). The authors highlighted that advanced age (>70 years), failing of vessel recanalization, duration of vessel occlusion, presence of atrial fibrillation and pre-treatment NIHSS >20 were associated with worse clinical outcomes. Jadhav et al. (49) included 107 subjects with acute stenting of symptomatic ICAO achieving successful recanalization in 92%, stabilization or improvement of NIHSS in 83% and favorable clinical outcome in 65% of cases. Interestingly, in this study median onset-to-treatment-time was 25 hours with still 93% of patients having perfusion-mismatch and 42% showing clinical-imaging mismatch, further highlighting the broadened time windows in endovascular treatment strategies in selected patients compared to medical treatment alone. Distal embolization of thrombotic material occurred in 22% requiring intra-arterial treatment in 17%. One-year post-treatment, 15% of subjects had re-stenosis in stented cervical arteries with necessity of re-intervention.

Conclusively if available, thrombectomy is a feasible method with good rates of vessel recanalization and positive impact on patient outcome within 3 months after ischemic stroke in patients with acute ICAO. The additional effect of i.v. thrombolysis is proven in patients with tandem pathologies and should not be withheld in those with isolated extracranial acute ICAO. As no randomized controlled trials exist for the latter group, the current data on treatment effects stem from observational studies only. The clear benefit of a combined approach in isolated extracranial acute ICAO therefore is unknown but has to be weighed against a high risk of distal embolization in isolated extracranial acute ICAO.

Approach: neurosurgery—STA-MCA bypass

The first bypasses between the superficial temporal and the middle cerebral arteries (STA-MCA bypass) were performed in the late 60ies (50) in patients with ICA or MCA occlusions. Even though this technique was mainly used for subacute vessel occlusions followed by chronic cerebrovascular insufficiency, it has also been applied to the acute stroke setting. Whereas older studies report high mortality rates of 15% in acute cerebral bypass (51) more recent publications show high numbers of flow augmentation or flow preservation by extra-intracranial bypass surgery. Horiuchi et al. analyzed 59 patients with acute bypass surgery, showing significantly improved collateral flow and prevention of new infarction, with 1.6% deaths (due to myocardial infarction) and 16% morbidity (combined minor and major) (52). Several case series from the pre-thrombectomy era have been published, one included 7 patients with acute symptomatic ICAO (one with M2 occlusion where additional embolectomy was done) with a high DWI-ASPECT score [8-10] and a reduced cerebral blood flow in single-photon emission computed tomography. STA-MCA bypass was performed 1.5 to 23 (median 6) hours after symptom worsening and 7 to 112 (median 21) hours after symptom onset. Early neurological improvement at day 3 after surgery was observed in 3 patients (43%) and 6 patients (86%) had a good functional outcome (mRS ≤2) 6 months later (53). Of 21 patients reported in a single center series that were ineligible for or had no successful recanalization by mechanical thrombectomy, 10 had a cervical ICAO that was inaccessible to carotid endarterectomy (CEA) and showed a small infarct core with a substantial perfusion mismatch. STA-MCA bypass was performed in 6 patients 5 to 9 hours after clinical worsening, in 3 patients 1 day and in 1 patient 7 days after stroke onset without subsequent worsening. In total, 70% achieved good functional outcome (mRS ≤2) after 3 months (54).

STA-MCA bypass surgery has been regularly performed for decades in ICA atherosclerosis. However, three large randomized trials of bypass procedure in patients with subacute symptomatic high grade ICA or MCA atherosclerotic stenosis or occlusion (55) or subacute symptomatic ICA or MCA occlusion with hemodynamic cerebral ischemia defined by oxygen-extraction positron emission tomography (56) could not demonstrate a clinical benefit of bypass surgery. The COSS trial (56) showed comparable rates of ipsilateral stroke at 2 years in the surgical and medical group (21% vs. 22.7%, P=0.78), however, the ipsilateral ischemic stroke rate after the second postoperative day was 9% in the surgical and 22.7% in the medical group (57). On the one hand medical therapy has improved mainly due to the introduction of statins, while the perioperative stroke rate was exceedingly high in COSS. Studies from large centers have reported 30-day stroke rates of less than 5% (58-60) calling for specialized cerebrovascular centers (61,62). Nevertheless, the failure of the bypass trials has nearly led to abandonment of this technique, although acute or subacute ICA or MCA occlusion, not amenable to medical or endovascular treatment may well benefit from rapid revascularization.

In summary, STA-MCA bypass surgery is not the first line therapy for acute extracranial ICAO and its rate has markedly declined over the last decades parallel with the advances of other available techniques. Case series of highly selected patients with symptomatic large vessel occlusion and subsequent neurological worsening, a small infarct core and a large perfusion deficit treated in specialized centers reported that bypass surgery was save. Early neurological improvement was reported in 46% (5 out of 11) patients and good functional outcome (mRS 2) was documented in 71% (15 out of 21) patients with a preoperative mean NIHSS of 13.1 (SD 4.7; median 12, range 5–24). These results differ little from an observational study of ICAO treated with i.v. and/or i.a. thrombolysis alone that reported a good functional outcome in 77% (13 out of 17) patients with a mean NIHSS 11.4 (SD 4.2) (63). Yet, as the natural course of clinically instable patients with small infarct core and large perfusion mismatch might be less favorable, STA-MCA bypass surgery should be seen as an option for very selected patients where medical or interventional therapy is not appropriate or has already failed.

Approach: vascular surgery—endarterectomy

CEA is well established in the treatment of symptomatic extra-cranial carotid artery stenosis (64). In this setting, urgent CEA is indicated, due to the considerable risk of early ischemic stroke recurrence, and a safe and effective treatment option if performed within 14 days after initial event (65-67).

The role of emergent surgical CEA in acute ICAO is limited, mostly due to the scarce evidence in the field. To date, no randomized controlled trial investigating the effectiveness and safety of acute CEA in ICAO patients exist, only case series which are mostly limited due to their small sample sizes (60,68). A recent literature meta-analysis of 10 articles totalling 175 patients reported favourable outcome after acute surgical desobliteration of acute symptomatic ICAO with a high recanalization rate of 93% and mRS 0–2 in short term follow-up of 62% and a low rate of peri- and postoperative complications such as intracerebral hemorrhage, early re-occlusion or in-hospital stroke (69). Still, emergent CEA did take a back seat in treatment consideration of acute symptomatic ICAO, especially due to expected perioperative risk of the more invasive method compared to intra-arterial recanalization procedures. When considering acute CEA patient selection seems essential. In 2008, a single centre series of 35 patients with acute symptomatic ICAO concluded that restoration of blood flow can only be achieved in the acute stage in 86% of cases with a moderate risk of neurological worsening or death (12%). Patients were carefully selected by a thorough preoperative diagnostic work-up including diffusion- and perfusion weighted imaging to determine salvageable tissue (70). This pilot study was supported by later studies showing that in subjects with mismatch in perfusion imaging (60), recanalization rates (95–100%) and functional outcome mRS ≤2 in 40–80% after 3 months are favorable with mortality rates being similar to endovascular treatments (15,68,71-76). A small case series of another promising group of patients with isolated ICAO looked at 6 subjects with moderate to severe strokes and compensated ipsilateral perfusion in CT perfusion imaging. Five of 6 patients responded well to acute CEA within the first hours after stroke onset (68). In this setting, demonstration of distal ICA patency is essential and technical success depends on the age of the thrombus (77).

CEA after recanalization (spontaneous, iv thrombolysis, mechanical thrombectomy) of ICAO with a residual high-grade stenosis is a viable treatment option in secondary stroke prevention 2 to 14 days after stroke (78-80). A recent study also highlighted that emergent CEA of a residual stenosis can be performed safely (75). Also, studies investigating CEA of asymptomatic stenosis contralateral to the acute ICAO have suggested beneficial outcomes due to collateral blood flow assistance reducing the risk of future stroke (81,82).

In conclusion, the few articles focussing on surgical recanalization of acute ICAO suggest it to be a safe and a possible treatment option, however, critically dependent on patient selection.

Conclusions

When considering the acute management of extracranial ICAO, one has to differentiate between those with and without intracranial large vessel occlusion.

What we know from numerous endovascular thrombectomy trials is that early recanalization of the intracranial vessel occlusion is the most important parameter contributing to favorable outcome in ischemic stroke (33-37). Therefore, in patients with tandem pathologies a combined treatment of both the extracranial (with or without stenting) and intracranial occlusion through an endovascular (preferably retrograde) approach and i.v. thrombolysis is the standard therapy (38-41). As we know from the pre-thrombectomy-era, i.v. thrombolysis alone only has an uncertain and at best moderate effect on recanalization and outcome (1,6,26-28). Furthermore, i.v. thrombolysis is only an approved therapy option within the first 4.5 hours of ischemic symptom onset (label). In the rare event that intra-arterial procedures of the extracranially occluded ICA are not feasible or fail, surgical approaches such as CEA and bypass surgery are viable salvage therapy options. CEA is especially indicated if residual high-grade stenosis persists after initial extracranial angioplasty without stenting (78-80). The timing of CEA is dependent on infarct volume. Additionally, in the long run patients might benefit of CEA of a high grade contralateral carotid artery stenosis through assistance of collateral blood flow to the site of persistent ICAO (81,82). STA-MCA bypass surgery is a save therapy if medical and interventional approaches are contraindicated or fail. Its safety though is reliant on proper patient selection and should be performed in centers with expertise in the field of vascular neurosurgery.

The best management of extracranial acute ICAO without subsequent intracranial large vessel occlusion is unclear because no randomized controlled trials exist. Consequently, therapeutic approaches differ substantially between centers. In general, i.v. thrombolysis is indicated in acute ischemic stroke irrespective of the extracranial vessel status and must not be withheld when applied within the label (26,29). Endovascular revascularization of the acute ICAO comes with high risk of distal embolization (one fifth of cases) (49). Therefore, intervention should be restricted to subjects with minor neurological deficits and a high risk of clinical worsening or in those with substantial neurological deficits and a large penumbra. In both instances, collateral blood flow is on the verge of decompensation, yet parameters to estimate the risk for clinical worsening are ill-defined and have not been applied in larger cohorts. Clinically, low-flow TIAs like limb-shaking or retinal claudication (83) as well as dynamic neurological deficits induced by orthostatic maneuvers or by a drop in systemic blood pressure are indicative of insufficient collateralization. Cerebral blood flow can be measured by transcranial doppler ultrasound. A pseudo-venous flow pattern or impaired flow-reserve in the breath holding (or CO2 inhalation) test indicating a maximal activated autoreserve in the MCA might serve as prognostic tool, yet has not been widely studied in this setting (84-86). Computed tomography or magnet resonance imaging perfusion imaging is well established to visualize the penumbra in ischemic stroke and has been successfully applied in randomized controlled thrombectomy trials (87,88), yet a clear imaging definition of low-flow situations has yet to be established. Advanced functional imaging like 123I-IMP single-photon emission computed tomography with and without acetazolamide loading or H2 15O-Positron emission tomography imaging is rarely available in the acute stroke setting. Studies applying these imaging to select patients for STA/MCA bypass in the subacute stroke phase (56,59) failed to show a benefit.

In Summary, the mainstay of the acute management of ICAO is i.v. thrombolysis when given within the label and mechanical thrombectomy if intracranial large vessel occlusion is present as well. There is a subgroup of instable patients with isolated acute ICAO that probably benefit from acute recanalization procedures. More research on prognostic parameters in this setting to better characterize the risk of clinical worsening and to better define the time-window of intervention is needed.

The article’s supplementary files as